For the quarter ending 2025-09-30, NUVB-WT had $63,174K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -168,035 |
| Stock-based compensation | 27,906 |
| Depreciation and amortization | 1,200 |
| Non-cash lease expense | 281 |
| Non-cash interest on revenue interest financing agreement | -5,121 |
| Amortization of debt issuance costs | 335 |
| Change in fair value of warrant liability | -315 |
| Amortization of premium on marketable securities | 4,096 |
| Realized (gain) loss on marketable securities | 2 |
| Net loss on disposal of fixed assets | -30 |
| Unrealized foreign currency transaction loss | 415 |
| Acquired in-process research and development | 0 |
| Accounts receivable | -4,399 |
| Prepaid expenses and other current assets | 1,655 |
| Inventory | 5,710 |
| Interest receivable on marketable securities | 1,957 |
| Other non-current assets | 701 |
| Accounts payable | 9,012 |
| Contract liabilities | 8,838 |
| Accrued expenses | -254 |
| Net cash used in operating activities | -143,694 |
| Cash acquired from anheart acquisition | 0 |
| Transaction costs related to anheart acquisition | 0 |
| Purchases of marketable securities | 309,515 |
| Proceeds from sale of marketable securities | 330,217 |
| Cash paid for capitalized market approval intangibles | 8,000 |
| Purchases of property and equipment | 265 |
| Net cash provided by investing activities | 12,437 |
| Proceeds from borrowings, net of debt issuance costs and debt discounts | 48,901 |
| Proceeds from revenue interest financing agreement | -150,000 |
| Payments on borrowings | 700 |
| Payments of debt issuance costs | 6,596 |
| Payment on revenue interest financing agreement | 68 |
| Proceeds from issuance of common stock under espp | -533 |
| Proceeds from exercises of options | 2,402 |
| Net cash provided by financing activities | 194,472 |
| Effect of foreign exchange rate changes on cash and cash equivalents | -41 |
| Net increase (decrease) in cash and cash equivalents | 63,174 |
| Cash and cash equivalents at beginning of period | 35,723 |
| Cash and cash equivalents at end of period | 98,897 |
Nuvation Bio Inc. (NUVB-WT)
Nuvation Bio Inc. (NUVB-WT)